Multimodal treatment lies at the heart of the improvement in cancer cure rates. However, the more aggressive the treatment, the more adverse effects in normal tissues can be anticipated. Against this background, a major paradigm shift has taken place in that there is a new focus on cancer survivorship and quality of life: the life worth saving must be worth living. This volume is based on the CURED II conference held in May 2007, which was attended...